NCT03274258View on ClinicalTrials.gov

Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Kidney Medullary CarcinomaLoss of INI 1 Protein ExpressionStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8
Interventions
BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER